Durmuş Ali ÇETİN, Ebubekir GÜNDEŞ, ULAŞ ADAY, Hüseyin ÇİYİLTEPE, Kamuran DEĞER CUMHUR, MUSTAFA DUMAN

Metastatik Kolon Kanseri Tedavisinde Bevacizumab Sonrası İnce Barsak Perforasyonu: Nadir Bir Olgu

Bevacizumab, vasküler endotelyal büyüme faktör mole- külünü hedef alan bir monoklonal antikordur. Metasta- tik kolorektal kanserlerde klinik ajan olarak umut verici olduğu gösterilmiştir. Metastatik kolorektal kanserlerde kemoterapötik ajanlar ile kombine kullanılmaktadır. Beva- cizumab iyi tolere edilebilen tedavi ajanlarından olmasına rağmen ciddi komplikasyonları açısından dikkatli olunma- lıdır. Literatürde olgu sunumları ile sınırlı az sayıda ince barsak perforasyonu bildirilmiştir. 45 yaşında metastatik kolon kanseri nedeniyle opere edilen ve bevacizumab te- davisi sonrası ince barsak perforasyonu gelişen olgumu- zu literatür eşliğinde sunmayı amaçladık

Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case

Bevacizumab is a monoclonal antibody which is targeting to vascular endothelial growth factor. It has been shown to be a promising drug on metastatic colorectal cancer and is combined with chemotherapeutic agents. One should be aware of serious complications even though bevacizumab is a well-tolerated drug. There are a few in- testinal perforation cases that have been reported in the oncologic surgery literature related to the bevacizumab treatment. In this case report, we aimed to represent a 45 years old man who was diagnosed with intestinal per- foration after bevacizumab treatment ten months after a metastatic colon cancer surgery

PDF

___

1. Shih T, Lindley C. Bevacizumab: an angiogenesis inhi- bitor for the treatment of solid malignancies. Clin Ther 2006;28:1779- 1802. 2. Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2006;4:808- 821. 3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. 4. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in pa- tients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24:3354-3360. 5. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989. 6. Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with be- vacizumab. Am J Health Syst Pharm 2009; 66:999-1013. 7. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007;14:1860-1869. 8. Badgwell BD, Camp ER, Feig B, et al. Management of be- vacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008;19:577-582. 9. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Sur- gical wound healing complications in metastatic colorec- tal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-180. 10. Choi YI, Lee SH, Ahn BK, et al. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat 2008;40:33-35.